Women who use depo-subQ provera 104 may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.
It is unknown if use of depo-subQ provera 104 during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.
depo-subQ provera 104 should be used long-term (e.g., longer than 2 years) only if other methods of birth control are inadequate (see WARNINGS, section 1).
depo-subQ provera 104™
medroxyprogesterone acetate injectable suspension
depo-subQ provera 104 contains medroxyprogesterone acetate (MPA), a derivative of progesterone, as its active ingredient. Medroxyprogesterone acetate is active by the parenteral and oral routes of administration. It is a white to off-white, odorless crystalline powder that is stable in air and that melts between 205° and 209°C. It is freely soluble in chloroform, soluble in acetone and dioxane, sparingly soluble in alcohol and methanol, slightly soluble in ether, and insoluble in water.
depo-subQ provera 104 is indicated for the prevention of pregnancy in women of child bearing potential.
depo-subQ provera 104 also is indicated for management of endometriosis-associated pain.
Published Studies Related to Depo-Subq Provera (Medroxyprogesterone Subcutaneous)
Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone
acetate for the treatment of endometriosis: effects on bone mineral density. 
This randomized double-blind study, with 24-week treatment and 24-week
posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg
twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on
bone mineral density (BMD), in women with endometriosis-associated pain (n =
Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial. [2010.08]
BACKGROUND: The objectives of this study were to assess the feasibility of administering subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in a pharmacy setting and assess patient satisfaction... CONCLUSION: Administration of DMPA-SC by pharmacists in a pharmacy setting is feasible. Continuation rates and patient satisfaction with DMPA-SC and the pharmacy setting were comparable to those who received DMPA-SC in a family planning clinic. Copyright 2010 Elsevier Inc. All rights reserved.
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]
Medroxyprogesterone acetate (MPA) is widely known for its use in combination hormone therapy for postmenopausal women. However, MPA is also commonly used in young women for contraception and treatment of a number of gynecological conditions...
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. [2007.12.01]
BACKGROUND: Few randomized trials have compared the survival benefit of interferon-alfa over controls in metastatic renal cell carcinoma, and none has been performed using interleukin-2. The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments... CONCLUSIONS: Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity. Newly available angiogenesis inhibitors should be preferred for these patients. Copyright (c) 2007 American Cancer Society.
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis : results of a randomized controlled trial. [2007.10.11]
BACKGROUND.: Few randomized trials have compared the survival benefit of interferon-alfa over controls in metastatic renal cell carcinoma, and none has been performed using interleukin-2. The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments...
Clinical Trials Related to Depo-Subq Provera (Medroxyprogesterone Subcutaneous)
Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda [Completed]
The purpose of this study is to assess acceptability and side effects of a low-dose
injectable contraceptive formulation which is delivered under the skin (subcutaneously), as
compared with injectable contraception delivered into the muscle (intramuscularly) among
adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable
contraception. The investigators will also assess experiences experiences delivering these
two types of injections among health care providers working within the HIV care clinics.
Acceptability of Depo-subQ in Uniject [Completed]
This is an observational study to assess the experience of current depot medroxyprogesterone
acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject
and offer recommendations for the introduction of this method.
PK of Depo SubQ Injected in the Upper Arm [Completed]
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods [Not yet recruiting]
This is a randomized, multi-center, parallel-group study to evaluate the pharmacodynamics
(PD) of Medroxyprogesterone Acetate (MPA) after a single subcutaneous (SC) injection of
150mg/mL or 300mg/2mL Depo-Provera CI in the abdomen of women of reproductive age with a
confirmed ovulatory baseline cycle.
Safety and Efficacy Study of NBI-56418 in Endometriosis [Completed]
This study is designed to see how a research compound (NBI-56418) works compared to DMPA-SC
(also known as depo-provera) in women with endometriosis and to see how both may affect bone
Page last updated: 2015-08-10